[Xeloda.sup.TM] (capecitabine), produced by Hoffmann-La Roche Inc., has been granted accelerated approval as a new oral treatment available for women with tumors resistant to treatment by other means. Xeloda is converted to 5-fluorouracil upon oral administration and is approved for early for use in treating life-threatening conditions for which no acceptable alternative treatments exist or which provides a meaningful therapeutic benefit over existing treatments.
Study results show tumor shrinkage in 18.5 percent of patients taking Xeloda. Diarrhea, nausea, vomiting, inf1ammation of the mouth, "hand-foot syndrome" (swelling in the hands and feet), painful rash and mild bone marrow suppression were seen in about 30 percent of subjects. but side effects usually improved after dosage reduction or therapy cessation.
COPYRIGHT 1998 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group